{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:41:02Z","timestamp":1792654862488,"version":"4.5.0"},"reference-count":128,"publisher":"American Chemical Society (ACS)","issue":"1","license":[{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_ccby_termsofuse.html"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Radiolabeled peptides are a relatively new, very specific radiotracer group, which is still expanding. This group is very diverse in terms of peptide size. It contains very small structures containing several amino acids and whole antibodies. Moreover, radiolabeled peptides are diverse in terms of the binding aim and therapeutic or diagnostic applications. The majority of this class of radiotracers is utilized in oncology, where the same structure can be used in therapy and diagnostic imaging by varying the radionuclide. In this study, we collected new reports of radiolabeled peptide applications in diagnosis and therapy in oncology and other fields of medicine. Radiolabeled peptides are also increasingly being used in rheumatology, cardiac imaging, or neurology. The studies collected in this review concern new therapeutic and diagnostic procedures in humans and new structures tested on animals. We also performed an analysis of clinical trials, which concerns application of radiolabeled peptides and antibodies that were reported in the clinicaltrials.gov database between 2008 and 2018.<\/jats:p>","DOI":"10.1021\/acs.bioconjchem.0c00617","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T12:40:30Z","timestamp":1608208830000},"page":"25-42","source":"Crossref","is-referenced-by-count":75,"title":["Radiolabeled Peptides and Antibodies in Medicine"],"prefix":"10.1021","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2951-0867","authenticated-orcid":true,"given":"Pawe\u0142","family":"Kre\u0328cisz","sequence":"first","affiliation":[{"name":"Medical University of Lodz , , Muszyn\u0301skiego 1 , ,","place":["Lodz, Poland, 90-151"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6497-1565","authenticated-orcid":true,"given":"Kamila","family":"Czarnecka","sequence":"additional","affiliation":[{"name":"Medical University of Lodz , , Muszyn\u0301skiego 1 , ,","place":["Lodz, Poland, 90-151"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7117-9621","authenticated-orcid":true,"given":"Leszek","family":"Kro\u0301licki","sequence":"additional","affiliation":[{"name":"Medical University of Warsaw , , ul. Banacha 1 a , , ,","place":["Warsaw, Poland, 02-097"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7171-4524","authenticated-orcid":true,"given":"Elz\u0307bieta","family":"Mikiciuk-Olasik","sequence":"additional","affiliation":[{"name":"Medical University of Lodz , , Muszyn\u0301skiego 1 , ,","place":["Lodz, Poland, 90-151"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3438-7509","authenticated-orcid":true,"given":"Pawe\u0142","family":"Szyman\u0301ski","sequence":"additional","affiliation":[{"name":"Medical University of Lodz , , Muszyn\u0301skiego 1 , ,","place":["Lodz, Poland, 90-151"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"issue":"12","key":"2026090301450828100_cit1","doi-asserted-by":"publisher","first-page":"20536","DOI":"10.3390\/molecules191220536","article-title":"F-18-Labeled Peptides:\nThe Future Is Bright","volume":"19","author":"Richter","year":"2014","journal-title":"Molecules"},{"issue":"8632","key":"2026090301450828100_cit2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0140-6736(89)91258-0","article-title":"LOCALIZATION\nOF ENDOCRINE-RELATED TUMORS WITH RADIOIODINATED ANALOG OF SOMATOSTATIN","volume":"333","author":"Krenning","year":"1989","journal-title":"Lancet"},{"issue":"8","key":"2026090301450828100_cit3","first-page":"1384","article-title":"Detecting\nDeep Venous Thrombosis with Tc-99m-Labeled\nSynthetic Peptide P280","volume":"36","author":"Muto","year":"1995","journal-title":"J. Nucl. Med."},{"issue":"5","key":"2026090301450828100_cit4","first-page":"775","article-title":"Thrombus\nimaging with a technetium-99m-labeled, activated\nplatelet receptor-binding peptide","volume":"37","author":"ListerJames","year":"1996","journal-title":"J. Nucl.\nMed."},{"issue":"2","key":"2026090301450828100_cit5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1089\/cbr.2007.0435","article-title":"Improvement strategies\nfor peptide receptor scintigraphy and radionuclide therapy","volume":"23","author":"de Visser","year":"2008","journal-title":"Cancer Biother.Radiopharm."},{"issue":"5","key":"2026090301450828100_cit6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/JCO.2005.03.8471","article-title":"Antibody\npretargeting advances cancer radioimmunodetection and radioimmunotherapy","volume":"24","author":"Goldenberg","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"2026090301450828100_cit7","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1007\/s12094-018-02027-1","article-title":"Time for radioimmunotherapy: an overview to bring improvements in\nclinical practice","volume":"21","author":"Leaman Alcibar","year":"2019","journal-title":"Clin. Transl. Oncol."},{"issue":"3","key":"2026090301450828100_cit8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1021\/bc100437q","article-title":"Rapid and Simple One-Step F-18 Labeling\nof Peptides","volume":"22","author":"Jacobson","year":"2011","journal-title":"Bioconjugate Chem."},{"issue":"5","key":"2026090301450828100_cit9","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.bbagen.2010.02.002","article-title":"Radiolabelled\nproteins for positron emission tomography:\nPros and cons of labelling methods","volume":"1800","author":"Tolmachev","year":"2010","journal-title":"Biochim.\nBiophys. Acta, Gen. Subj."},{"key":"2026090301450828100_cit10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/978-1-4615-2462-5_31","article-title":"TECHNIQUES\nFOR DIRECT RADIOLABELING\nOF MONOCLONAL-ANTIBODIES","volume":"262","author":"Marek","year":"1994","journal-title":"Radiolabeled Blood\nElements: Recent Advances in Techniques and Applications"},{"issue":"4","key":"2026090301450828100_cit11","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1021\/bc0500600","article-title":"Water-soluble phosphines\nfor direct labeling of peptides\nwith technetium and rhenium: Insights from electrospray mass spectrometry","volume":"16","author":"Greenland","year":"2005","journal-title":"Bioconjugate Chem."},{"issue":"6","key":"2026090301450828100_cit12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1021\/bc00018a001","article-title":"Radiohalogenation\nof Proteins - an Overview of Radionuclides, Labeling Methods, And\nReagents for Conjugate Labeling","volume":"3","author":"Wilbur","year":"1992","journal-title":"Bioconjugate\nChem."},{"issue":"2","key":"2026090301450828100_cit13","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.apradiso.2010.09.023","article-title":"Automated radiochemical\nsynthesis of F-18 FBEM: A thiol reactive synthon for radiofluorination\nof peptides and proteins","volume":"69","author":"Kiesewetter","year":"2011","journal-title":"Appl. Radiat. Isot."},{"issue":"3","key":"2026090301450828100_cit14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/0883-2897(92)90111-B","article-title":"Labeling proteins with fluorine-18 using N-succinimidyl\n4-[18F]fluorobenzoate","volume":"19","author":"Vaidyanathan","year":"1992","journal-title":"International Journal\nof Radiation Applications and Instrumentation. Part B. Nuclear Medicine\nand Biology"},{"issue":"6","key":"2026090301450828100_cit15","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/0969-8043(94)90252-6","article-title":"Fluoroacylation\nagents based on small\nn.c.a. [18F]fluorocarboxylic acids","volume":"45","author":"Guhlke","year":"1994","journal-title":"Appl. Radiat.\nIsot."},{"issue":"17","key":"2026090301450828100_cit16","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.3390\/molecules25173924","article-title":"Automated Synthesis of Fluorine-18\nLabeled CXCR4 Ligand\nvia the Conjugation with Nicotinic AcidN-Hydroxysuccinimide Ester\n(6- F-18 SFPy)","volume":"25","author":"Basuli","year":"2020","journal-title":"Molecules"},{"issue":"12","key":"2026090301450828100_cit17","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1021\/acs.bioconjchem.6b00561","article-title":"Click Chemistry\nand Radiochemistry: The First 10 Years","volume":"27","author":"Meyer","year":"2016","journal-title":"Bioconjugate\nChem."},{"issue":"8","key":"2026090301450828100_cit18","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1021\/bc3002425","article-title":"F-18 Labeling\nProtocol of Peptides Based on Chemically Orthogonal Strain-Promoted\nCycloaddition under Physiologically Friendly Reaction Conditions","volume":"23","author":"Sachin","year":"2012","journal-title":"Bioconjugate Chem."},{"issue":"7","key":"2026090301450828100_cit19","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1021\/bc100137x","article-title":"Improved F-18 Labeling of Peptides\nwith a Fluoride-Aluminum-Chelate Complex","volume":"21","author":"McBride","year":"2010","journal-title":"Bioconjugate\nChem."},{"issue":"11","key":"2026090301450828100_cit20","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00259-002-0900-8","article-title":"Current use and future potential of organometallic\nradiopharmaceuticals","volume":"29","author":"Schibli","year":"2002","journal-title":"Eur. J. Nucl. Med. Mol.\nImaging"},{"issue":"5","key":"2026090301450828100_cit21","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1053\/j.semnuclmed.2017.05.007","article-title":"Clinical Applications\nof Radiolabeled\nPeptides for PET","volume":"47","author":"Jackson","year":"2017","journal-title":"Semin. Nucl. Med."},{"issue":"4","key":"2026090301450828100_cit22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.nucmedbio.2010.02.001","article-title":"ScVEGF-PEG-HBED-CC and scVEGF-PEG-NOTA conjugates:\ncomparison of easy-to-label recombinant proteins for Ga-68 PET imaging\nof VEGF receptors in angiogenic vasculature","volume":"37","author":"Eder","year":"2010","journal-title":"Nucl. Med. Biol."},{"key":"2026090301450828100_cit23","first-page":"215","volume-title":"68Ga-PET Radiopharmacy: A Generator-Based\nAlternative to\n18F-Radiopharmacy, Berlin, Heidelberg","author":"Maecke","year":"2007"},{"issue":"2","key":"2026090301450828100_cit24","first-page":"327","article-title":"Optimization of\nradioimmunotherapy of renal cell carcinoma: Labeling of monoclonal\nantibody cG250 with I-131, Y-90, Lu-177, or Re-186","volume":"45","author":"Brouwers","year":"2004","journal-title":"J. Nucl. Med."},{"issue":"7","key":"2026090301450828100_cit25","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/jps.23146","article-title":"Molecular Nanomedicine\nTowards Cancer: In-111-Labeled Nanoparticles","volume":"101","author":"Psimadas","year":"2012","journal-title":"J. Pharm. Sci."},{"issue":"7","key":"2026090301450828100_cit26","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1158\/1078-0432.CCR-05-2137","article-title":"Performance\nof immuno-positron emission tomography\nwith zirconium-89-labeled chimeric monoclonal antibody U36 in the\ndetection of lymph node metastases in head and neck cancer patients","volume":"12","author":"Borjesson","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"2026090301450828100_cit27","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.ica.2010.01.009","article-title":"Hydrazinonicotinic\nacid (HYNIC) - Coordination chemistry and applications in radiopharmaceutical\nchemistry","volume":"363","author":"Meszaros","year":"2010","journal-title":"Inorg. Chim. Acta"},{"issue":"23","key":"2026090301450828100_cit28","doi-asserted-by":"publisher","first-page":"6260","DOI":"10.1039\/c0dt01608j","article-title":"Synthesis and evaluation\nof analogues of HYNIC as bifunctional chelators for technetium","volume":"40","author":"Meszaros","year":"2011","journal-title":"Dalton Transactions"},{"issue":"6","key":"2026090301450828100_cit29","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1039\/C5NP00083A","article-title":"Molecular imaging\nprobes derived\nfrom natural peptides","volume":"33","author":"Charron","year":"2016","journal-title":"Nat. Prod. Rep."},{"issue":"4","key":"2026090301450828100_cit30","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S0969-8051(98)00118-8","article-title":"99m-technetium-labelled\npeptide-HYNIC conjugates: Effects\nof lipophilicity and stability on biodistribution","volume":"26","author":"Decristoforo","year":"1999","journal-title":"Nucl. Med. Biol."},{"issue":"3","key":"2026090301450828100_cit31","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s10967-019-06797-y","article-title":"Theranostic\nradionuclides: recent advances in production methodologies","volume":"322","author":"Qaim","year":"2019","journal-title":"J. Radioanal. Nucl. Chem."},{"issue":"2","key":"2026090301450828100_cit32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0733-8651(18)30109-7","article-title":"Dual-Isotope Myocardial\nPerfusion Spect with Rest Thallium-201\nand Stress Tc-99m Sestamibi","volume":"12","author":"Berman","year":"1994","journal-title":"Cardiology Clinics"},{"issue":"2","key":"2026090301450828100_cit33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/ph13020022","article-title":"Radiolabelled Peptides for Positron Emission Tomography\nand Endoradiotherapy in Oncology dagger","volume":"13","author":"Rangger","year":"2020","journal-title":"Pharmaceuticals"},{"key":"2026090301450828100_cit34","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.2174\/1568026620666200226104652","article-title":"Peptide Receptor\nRadionuclide Therapy:\nLooking Back, Looking Forward","volume":"20","author":"Feijtel","year":"2020","journal-title":"Curr. Top. Med.\nChem."},{"issue":"3","key":"2026090301450828100_cit35","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2174\/1874471010801030177","article-title":"Astatine Radiopharmaceuticals:\nProspects and Problems","volume":"1","author":"Vaidyanathan","year":"2008","journal-title":"Curr. Radiopharm."},{"issue":"6","key":"2026090301450828100_cit36","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1515\/ract-2017-2874","article-title":"Production, quality control, biodistribution\nand imaging studies of Lu-177-PSMA-617 in breast adenocarcinoma model","volume":"106","author":"Sharifi","year":"2018","journal-title":"Radiochim. Acta"},{"key":"2026090301450828100_cit37","doi-asserted-by":"publisher","first-page":"61S","DOI":"10.2967\/jnumed.116.186783","article-title":"Somatostatin\nReceptor Antagonists\nfor Imaging and Therapy","volume":"58","author":"Fani","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"2","key":"2026090301450828100_cit38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/MPA.0000000000000734","article-title":"Peptide\nReceptor Radionuclide Therapy Outcomes in a North American Cohort\nWith Metastatic Well-Differentiated Neuroendocrine Tumors","volume":"46","author":"Sharma","year":"2017","journal-title":"Pancreas"},{"issue":"3","key":"2026090301450828100_cit39","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.nucmedbio.2009.11.008","article-title":"In vivo binding\nof Ga-68 -DOTATOC to somatostatin receptors in neuroendocrine tumours\n- impact of peptide mass","volume":"37","author":"Velikyan","year":"2010","journal-title":"Nucl. Med. Biol."},{"key":"2026090301450828100_cit40","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ejmp.2017.06.024","article-title":"Prediction\nof time-integrated activity coefficients in PRRT using simulated dynamic\nPET and a pharmacokinetic model","volume":"42","author":"Hardiansyah","year":"2017","journal-title":"Physica Medica-European\nJournal of Medical Physics"},{"issue":"5","key":"2026090301450828100_cit41","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00259-015-3248-6","article-title":"The role of\npatient-based treatment\nplanning in peptide receptor radionuclide therapy","volume":"43","author":"Hardiansyah","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"9","key":"2026090301450828100_cit42","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1118\/1.4961012","article-title":"Time-integrated activity\ncoefficient estimation for radionuclide therapy using PET and a pharmacokinetic\nmodel: A simulation study on the effect of sampling schedule and noise","volume":"43","author":"Hardiansyah","year":"2016","journal-title":"Med. Phys."},{"key":"2026090301450828100_cit43","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2967\/jnumed.117.189712","article-title":"Therapy-related\nhematological malignancies after peptide receptor radionuclide therapy\nwith 177 Lu-DOTA-Octreotate: Incidence, course & predicting factors\nin patients with GEP-NETs","volume":"59","author":"Bergsma","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"2","key":"2026090301450828100_cit44","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.remn.2016.10.003","article-title":"Lu-177-DOTATATE\ntreatment in neuroendocrine tumours. A preliminary study","volume":"36","author":"Hervas","year":"2017","journal-title":"Revista Espanola De Medicina Nuclear E Imagen Molecular"},{"issue":"2","key":"2026090301450828100_cit45","doi-asserted-by":"publisher","first-page":"90","DOI":"10.7508\/aojnmb.2016.02.005","article-title":"Physiologically Based\nPharmacokinetic (PBPK) Model for Biodistribution of Radiolabeled Peptides\nin Patients with Neuroendocrine Tumours","volume":"4","author":"Gospavic","year":"2016","journal-title":"Asia\nOceania journal of nuclear medicine & biology"},{"issue":"4","key":"2026090301450828100_cit46","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1515\/iss-2017-0025","article-title":"Neoadjuvant\npeptide receptor radionuclide therapy and\nmodified multivisceral transplantation for an advanced small intestinal\nneuroendocrine neoplasm: an updated case report","volume":"2","author":"Clift","year":"2017","journal-title":"Innovative Surgical Sciences"},{"key":"2026090301450828100_cit47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5603\/EP.a2020.0014","article-title":"Effect of Peptide Receptor Radionuclide\nTherapy (PRRT) with tandem isotopes - [90Y]Y\/[177Lu]Lu-DOTATATE in\npatients with disseminated neuroendocrine tumours depending on qualification\n[18F]FDG PET\/CT in Polish multicenter experience - do we need [18F]FDG","author":"Zemczak","year":"2020","journal-title":"Endokrynol. Pol."},{"issue":"4","key":"2026090301450828100_cit48","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s00259-020-04690-5","article-title":"Tandem peptide receptor radionuclide\ntherapy using Y-90\/Lu-177-DOTATATE for neuroendocrine tumors efficacy\nand side-effects-polish multicenter experience","volume":"47","author":"Kunikowska","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"9","key":"2026090301450828100_cit49","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/RLU.0000000000001753","article-title":"Whole-Body\n68Ga-DOTANOC PET\/MRI Versus 68Ga-DOTANOC PET\/CT in Patients With Neuroendocrine\nTumors: A Prospective Study in 28 Patients","volume":"42","author":"Berzaczy","year":"2017","journal-title":"Clinical Nuclear Medicine"},{"issue":"44","key":"2026090301450828100_cit50","doi-asserted-by":"publisher","first-page":"16436","DOI":"10.1073\/pnas.0607761103","article-title":"Radiolabeled somatostatin\nreceptor antagonists are\npreferable to agonists for in vivo peptide receptor targeting of tumors","volume":"103","author":"Ginj","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"2026090301450828100_cit51","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2967\/jnumed.115.167007","article-title":"Comparison of the Therapeutic Response\nto Treatment with a Lu-177-Labeled Somatostatin Receptor Agonist and\nAntagonist in Preclinical Models","volume":"57","author":"Dalm","year":"2016","journal-title":"J. Nucl. Med."},{"issue":"8","key":"2026090301450828100_cit52","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.2967\/jnumed.114.138834","article-title":"Comparison of Somatostatin Receptor\nAgonist and Antagonist for Peptide Receptor Radionuclide Therapy:\nA Pilot Study","volume":"55","author":"Wild","year":"2014","journal-title":"J. Nucl. Med."},{"issue":"9","key":"2026090301450828100_cit53","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.2967\/jnumed.117.191684","article-title":"Biodistribution,\nPharmacokinetics,\nand Dosimetry of Lu-177-, Y-90-, and In-111-Labeled Somatostatin Receptor\nAntagonist OPS201 in Comparison to the Agonist Lu-177-DOTATATE: The\nMass Effect","volume":"58","author":"Nicolas","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"10","key":"2026090301450828100_cit54","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.2967\/jnumed.116.189035","article-title":"SSTR-Mediated\nImaging in Breast Cancer: Is There a\nRole for Radiolabeled Somatostatin Receptor Antagonists?","volume":"58","author":"Dalm","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"10","key":"2026090301450828100_cit55","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.2967\/jnumed.114.142000","article-title":"Targeting Neuropeptide\nReceptors for Cancer Imaging\nand Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y\nReceptors","volume":"55","author":"Morgat","year":"2014","journal-title":"J. Nucl. Med."},{"key":"2026090301450828100_cit56","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.peptides.2015.04.026","article-title":"Insights into bombesin\nreceptors and ligands: Highlighting recent advances","volume":"72","author":"Ramos-Alvarez","year":"2015","journal-title":"Peptides"},{"issue":"9","key":"2026090301450828100_cit57","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2967\/jnumed.116.188011","article-title":"Expression\nof Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association\nwith Pathologic, Biologic, and Clinical Parameters: A Study of 1,432\nPrimary Tumors","volume":"58","author":"Morgat","year":"2017","journal-title":"J. Nucl. Med."},{"key":"2026090301450828100_cit58","first-page":"S221","article-title":"Lu-177-AMBA Bombesin analogue in hormone refractory\nprostate cancer patients: A phase I escalation study with single-cycle\nadministrations","volume":"34","author":"Bodei","year":"2007","journal-title":"European Journal of Nuclear\nMedicine and Molecular Imaging"},{"issue":"1","key":"2026090301450828100_cit59","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2967\/jnumed.116.178889","article-title":"Theranostic Perspectives in Prostate Cancer with the\nGastrin Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical\nand First Clinical Results","volume":"58","author":"Nock","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"11","key":"2026090301450828100_cit60","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.3390\/molecules22111950","article-title":"NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics:\nFirst Results of a Preclinical Study with Ga-67 NeoBOMB1 in T-47D\nCells and Tumor-Bearing Mice","volume":"22","author":"Kaloudi","year":"2017","journal-title":"Molecules"},{"issue":"2","key":"2026090301450828100_cit61","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2967\/jnumed.116.176636","article-title":"Ga-68\/Lu-177-NeoBOMB1,\na Novel Radiolabeled\nGRPR Antagonist for Theranostic Use in Oncology","volume":"58","author":"Dalm","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"2","key":"2026090301450828100_cit62","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1021\/acs.bioconjchem.7b00726","article-title":"Positron Emission Tomography\nImaging of Prostate Cancer\nwith Ga-68-Labeled Gastrin-Releasing Peptide Receptor Agonist BBN7\u201314\nand Antagonist RM26","volume":"29","author":"Cheng","year":"2018","journal-title":"Bioconjugate Chem."},{"issue":"5","key":"2026090301450828100_cit63","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1021\/acs.jmedchem.7b01856","article-title":"Monomeric and Dimeric\nGa-68-Labeled Bombesin Analogues for Positron Emission Tomography\n(PET) Imaging of Tumors Expressing Gastrin-Releasing Peptide Receptors\n(GRPrs)","volume":"61","author":"Liolios","year":"2018","journal-title":"J. Med. Chem."},{"key":"2026090301450828100_cit64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1471-2407-11-293","article-title":"Differences in integrin\nexpression and signaling within human breast cancer cells","volume":"11","author":"Taherian","year":"2011","journal-title":"BMC Cancer"},{"issue":"3","key":"2026090301450828100_cit65","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/sj.bjc.6601576","article-title":"Integrins: roles in\ncancer development and as treatment\ntargets","volume":"90","author":"Jin","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"6","key":"2026090301450828100_cit66","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1007\/s00259-007-0692-y","article-title":"Ga-68-labeled\nmultimeric RGD peptides\nfor microPET imaging of integrin alpha(v)beta(3) expression","volume":"35","author":"Li","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"2026090301450828100_cit67","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/MNM.0000000000000065","article-title":"Kit preparation\nand biokinetics in women of Tc-99m-EDDA\/HYNIC-E-\nc(RGDfK) (2) for breast cancer imaging","volume":"35","author":"Ortiz-Arzate","year":"2014","journal-title":"Nucl.\nMed. Commun."},{"issue":"6","key":"2026090301450828100_cit68","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1089\/108497802320970244","article-title":"Comparison\nof a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting","volume":"17","author":"Janssen","year":"2002","journal-title":"Cancer Biother.Radiopharm."},{"issue":"4","key":"2026090301450828100_cit69","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.7150\/thno.22601","article-title":"Ga-68-BBN-RGD\nPET\/CT for GRPR and Integrin alpha(v)beta(3) Imaging\nin Patients with Breast Cancer","volume":"8","author":"Zhang","year":"2018","journal-title":"Theranostics"},{"issue":"12","key":"2026090301450828100_cit70","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1371\/journal.pone.0168248","article-title":"Ga-68-TRAP-(RGD)(3)\nHybrid Imaging for the In Vivo Monitoring of alpha(v)beta(3)-Integrin\nExpression as Biomarker of Anti-Angiogenic Therapy Effects in Experimental\nBreast Cancer","volume":"11","author":"Kazmierczak","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"2026090301450828100_cit71","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1210\/en.2004-0015","article-title":"Minireview: Glucagon-like\npeptides regulate cell proliferation\nand apoptosis in the pancreas, gut, and central nervous system","volume":"145","author":"Brubaker","year":"2004","journal-title":"Endocrinology"},{"key":"2026090301450828100_cit72","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1155\/2012\/470851","article-title":"Physiology and Emerging\nBiochemistry of the Glucagon-Like\nPeptide-1 Receptor","volume":"2012","author":"Willard","year":"2012","journal-title":"Exp. Diabetes Res."},{"key":"2026090301450828100_cit73","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2310\/7290.2014.00057","article-title":"Synthesis and Evaluation\nof Optical and PET GLP-1 Peptide Analogues for GLP-1R Imaging","volume":"14","author":"Azad","year":"2015","journal-title":"Mol. Imaging"},{"issue":"7","key":"2026090301450828100_cit74","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1056\/NEJMc0802045","article-title":"Glucagon-like\npeptide 1-receptor scans to localize occult insulinomas","volume":"359","author":"Wild","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"2026090301450828100_cit75","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1210\/jc.2009-1082","article-title":"Glucagon-Like Peptide-1\nReceptor Imaging for Localization\nof Insulinomas","volume":"94","author":"Christ","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"2026090301450828100_cit76","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.2967\/jnumed.115.159186","article-title":"Development\nof Ga-68- and Zr-89-Labeled Exendin-4 as Potential Radiotracers for\nthe Imaging of Insulinomas by PET","volume":"56","author":"Bauman","year":"2015","journal-title":"J. Nucl.\nMed."},{"issue":"13","key":"2026090301450828100_cit77","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1007\/s00259-018-4101-5","article-title":"Comparison of glucagon-like\npeptide-1 receptor (GLP-1R)\nPET\/CT, SPECT\/CT and 3T MRI for the localisation of occult insulinomas:\nevaluation of diagnostic accuracy in a prospective crossover imaging\nstudy","volume":"45","author":"Antwi","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"8","key":"2026090301450828100_cit78","doi-asserted-by":"publisher","first-page":"E285","DOI":"10.1097\/RLU.0000000000002155","article-title":"68Ga DOTA-Exendin\nPET\/CT for Detection of Insulinoma in a Patient With Persistent Hyperinsulinemic\nHypoglycemia","volume":"43","author":"Parihar","year":"2018","journal-title":"Clinical Nuclear Medicine"},{"issue":"2","key":"2026090301450828100_cit79","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11307-013-0691-2","article-title":"Cu-64- and Ga-68-Labelled Nle(14),Lys(40)(Ahx-NODAGA)NH2\n-Exendin-4 for Pancreatic Beta Cell Imaging in Rats","volume":"16","author":"Kirsi","year":"2014","journal-title":"Molecular Imaging and Biology"},{"key":"2026090301450828100_cit80","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41598-019-42172-3","article-title":"Evaluation\nof Ga-68 DO3A-VS-Cys(40)-Exendin-4 as a PET Probe for Imaging Human\nTransplanted Islets in the Liver","volume":"9","author":"Li","year":"2019","journal-title":"Sci. Rep."},{"key":"2026090301450828100_cit81","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.brainres.2018.08.022","article-title":"Age-related change\nof GLP-1R expression in rats can be detected by F-18 AlF-NOTA-MAL-Cys(39)-exendin-4","volume":"1698","author":"Wang","year":"2018","journal-title":"Brain Res."},{"issue":"11","key":"2026090301450828100_cit82","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.2174\/1381612043452640","article-title":"Chemokines\nand their receptors as\ntherapeutic targets: The role of the SDF-1\/CXCR4 axis","volume":"10","author":"Juarez","year":"2004","journal-title":"Curr. Pharm. Des."},{"issue":"8","key":"2026090301450828100_cit83","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s12149-018-1290-8","article-title":"CXCR4-directed theranostics\nin oncology and inflammation","volume":"32","author":"Kircher","year":"2018","journal-title":"Ann. Nucl. Med."},{"issue":"5263","key":"2026090301450828100_cit84","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1126\/science.272.5263.872","article-title":"HIV-1 entry cofactor:\nFunctional cDNA cloning of a seven-transmembrane, G protein-coupled\nreceptor","volume":"272","author":"Feng","year":"1996","journal-title":"Science"},{"key":"2026090301450828100_cit85","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/srep29338","article-title":"Immunophenotyping\nof rheumatoid arthritis reveals\na linkage between HLA-DRB1 genotype, CXCR4 expression on memory CD4(+)\nT cells, and disease activity","volume":"6","author":"Nagafuchi","year":"2016","journal-title":"Sci. Rep."},{"key":"2026090301450828100_cit86","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1146\/annurev.immunol.021908.132620","article-title":"Immune and Inflammatory\nMechanisms of Atherosclerosis","volume":"27","author":"Galkina","year":"2009","journal-title":"Annu. Rev. Immunol."},{"issue":"5","key":"2026090301450828100_cit87","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-17-1756","article-title":"CXCR4 Is a Potential\nTarget for Diagnostic PET\/CT Imaging in Barrett\u2019s Dysplasia\nand Esophageal Adenocarcinoma","volume":"24","author":"Fang","year":"2018","journal-title":"Clin. Cancer\nRes."},{"key":"2026090301450828100_cit88","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41398-017-0049-7","article-title":"CXCR4 involvement in neurodegenerative\ndiseases","volume":"8","author":"Bonham","year":"2018","journal-title":"Transl. Psychiatry"},{"issue":"10","key":"2026090301450828100_cit89","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1002\/cmdc.201100320","article-title":"PET Imaging\nof CXCR4 Receptors in Cancer by a New Optimized Ligand","volume":"6","author":"Demmer","year":"2011","journal-title":"ChemMedChem"},{"issue":"6","key":"2026090301450828100_cit90","doi-asserted-by":"publisher","first-page":"618","DOI":"10.7150\/thno.11251","article-title":"Disclosing\nthe CXCR4\nExpression in Lymphoproliferative Diseases by Targeted Molecular Imaging","volume":"5","author":"Wester","year":"2015","journal-title":"Theranostics"},{"key":"2026090301450828100_cit91","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fonc.2019.00503","article-title":"Ga-68 -Pentixafor PET\/CT for CXCR4-Mediated Imaging\nof Vestibular Schwannomas","volume":"9","author":"Breun","year":"2019","journal-title":"Front. Oncol."},{"issue":"8","key":"2026090301450828100_cit92","doi-asserted-by":"publisher","first-page":"882","DOI":"10.7150\/thno.12303","article-title":"Prospective Study of\nGa-68-NOTA-NFB: Radiation Dosimetry\nin Healthy Volunteers and First Application in Glioma Patients","volume":"5","author":"Wang","year":"2015","journal-title":"Theranostics"},{"issue":"1","key":"2026090301450828100_cit93","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11307-015-0872-2","article-title":"Al F-18 NOTA-T140\nPeptide for Noninvasive Visualization of CXCR4 Expression","volume":"18","author":"Yan","year":"2016","journal-title":"Molecular Imaging and Biology"},{"issue":"9","key":"2026090301450828100_cit94","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.7150\/thno.19119","article-title":"Lu-177 pentixather: Comprehensive Preclinical\nCharacterization of a First CXCR4-directed Endoradiotherapeutic Agent","volume":"7","author":"Schottelius","year":"2017","journal-title":"Theranostics"},{"issue":"11","key":"2026090301450828100_cit95","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1021\/acs.molpharmaceut.9b00808","article-title":"Ga-68 Ga\/ Lu-177 Lu-BL01,\na Novel Theranostic Pair\nfor Targeting C-X-C Chemokine Receptor 4","volume":"16","author":"Lau","year":"2019","journal-title":"Mol.\nPharmaceutics"},{"issue":"3","key":"2026090301450828100_cit96","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/jcla.1860030302","article-title":"Characteristics\nand Distribution\nof Receptors for D-Trp6 -Luteinizing Hormone-Releasing Hormone, Somatostatin,\nEpidermal Growth-Factor, And Sex Steroids in 500 Biopsy Samples of\nHuman-Breast Cancer","volume":"3","author":"Fekete","year":"1989","journal-title":"J. Clin. Lab. Anal."},{"issue":"3","key":"2026090301450828100_cit97","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1210\/jcem-64-3-425","article-title":"Gonadotropin-Releasing-Hormone\n(Gnrh)-Binding Sites in Human-Breast Cancer Cell-Lines and Inhibitory\nEffects of Gnrh Antagonists","volume":"64","author":"Eidne","year":"1987","journal-title":"J. Clin. Endocrinol.\nMetab."},{"issue":"5","key":"2026090301450828100_cit98","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/00006676-198910000-00001","article-title":"Membrane-Receptors\nfor Peptides in Experimental and Human Pancreatic Cancers","volume":"4","author":"Fekete","year":"1989","journal-title":"Pancreas"},{"issue":"6","key":"2026090301450828100_cit99","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s12149-016-1074-y","article-title":"Development\nof a Ga-68-peptide tracer\nfor PET GnRH1-imaging","volume":"30","author":"Zoghi","year":"2016","journal-title":"Ann. Nucl. Med."},{"issue":"8","key":"2026090301450828100_cit100","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1371\/journal.pone.0135824","article-title":"uPAR Expression Pattern in Patients\nwith Urothelial Carcinoma of the Bladder - Possible Clinical Implications","volume":"10","author":"Dohn","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"2026090301450828100_cit101","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/cpf.12037","article-title":"Urokinase-type plasminogen activator\nreceptor (uPAR) as a promising new imaging target: potential clinical\napplications","volume":"33","author":"Persson","year":"2013","journal-title":"Clin. Physiol. Funct. Imaging"},{"issue":"3","key":"2026090301450828100_cit102","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2967\/jnumed.116.178970","article-title":"Safety, Dosimetry, and Tumor Detection Ability of Ga-68-NOTA-AE105:\nFirst-in-Human Study of a Novel Radioligand for uPAR PET Imaging","volume":"58","author":"Skovgaard","year":"2017","journal-title":"J. Nucl. Med."},{"key":"2026090301450828100_cit103","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/1536012118801223","article-title":"Application\nof Immuno-PET in Antibody-Drug\nConjugate Development","volume":"17","author":"Carmon","year":"2018","journal-title":"Mol. Imaging"},{"issue":"5","key":"2026090301450828100_cit104","first-page":"531","article-title":"Monoclonal-Antibodies\nin Nuclear-Medicine","volume":"26","author":"Keenan","year":"1985","journal-title":"J. Nucl. Med."},{"issue":"1","key":"2026090301450828100_cit105","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S1246-7820(01)00210-5","article-title":"Recombinant monoclonal antibody technology","volume":"9","author":"Siegel","year":"2002","journal-title":"Transfusion Clinique Et Biologique"},{"issue":"13","key":"2026090301450828100_cit106","first-page":"2911","article-title":"Antibody biotechnology","volume":"8","author":"Benjouad","year":"2009","journal-title":"African\nJournal of Biotechnology"},{"issue":"1","key":"2026090301450828100_cit107","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3109\/08830189509061738","article-title":"Human Antibodies from Transgenic\nMice","volume":"13","author":"Lonberg","year":"1995","journal-title":"Int. Rev. Immunol."},{"issue":"1","key":"2026090301450828100_cit108","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/ijms18010057","article-title":"Immuno-PET\nfor Clinical Theranostic Approaches","volume":"18","author":"Bailly","year":"2017","journal-title":"Int. J.\nMol. Sci."},{"key":"2026090301450828100_cit109","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fmed.2019.00124","article-title":"Clinical Results in Medullary Thyroid Carcinoma\nSuggest High Potential\nof Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches","volume":"6","author":"Bodet-Milin","year":"2019","journal-title":"Front. Med."},{"issue":"8","key":"2026090301450828100_cit110","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1007\/s00259-015-3025-6","article-title":"Tumour\ntargeting and radiation dose of radioimmunotherapy with Y-90-rituximab\nin CD20+B-cell lymphoma as predicted by Zr-89-rituximab immuno-PET:\nimpact of preloading with unlabelled rituximab","volume":"42","author":"Muylle","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"3","key":"2026090301450828100_cit111","doi-asserted-by":"publisher","first-page":"20160136","DOI":"10.1259\/bjrcr.20160136","article-title":"Ga-68-DTPA Anti-HER2 positron emission tomography\/CT\nsuccessfully predicts the overexpression of human epidermal growth\nfactor receptor in lung metastases from breast cancer","volume":"3","author":"Pitalua-Cortes","year":"2017","journal-title":"Bjr Case Reports"},{"key":"2026090301450828100_cit112","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41598-018-21283-3","article-title":"Evaluation of HER2-specific peptide ligand for its employment as\nradiolabeled imaging probe","volume":"8","author":"Honarvar","year":"2018","journal-title":"Sci. Rep."},{"issue":"7","key":"2026090301450828100_cit113","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.7150\/jca.18070","article-title":"PET of HER2 Expression\nwith a Novel\n(FAl)-F-18 Labeled Affibody","volume":"8","author":"Xu","year":"2017","journal-title":"J. Cancer"},{"key":"2026090301450828100_cit114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/8565802","article-title":"Comparative\nEvaluation of Anti-HER2 Affibody Molecules\nLabeled with Cu-64 Using NOTA and NODAGA","volume":"2017","author":"Tolmachev","year":"2017","journal-title":"Contrast\nMedia Mol. Imaging"},{"issue":"8","key":"2026090301450828100_cit115","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s00259-017-3650-3","article-title":"Intra-image referencing\nfor simplified assessment of\nHER2-expression in breast cancer metastases using the Affibody molecule\nABY-025 with PET and SPECT","volume":"44","author":"Sandberg","year":"2017","journal-title":"Eur. J. Nucl. Med.\nMol. Imaging"},{"issue":"4","key":"2026090301450828100_cit116","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.nucmedbio.2013.12.018","article-title":"Visualizing inflammation\nactivity in rheumatoid arthritis with Tc-99 m Anti-CD4-mAb fragment\nscintigraphy","volume":"41","author":"Steinhoff","year":"2014","journal-title":"Nucl. Med. Biol."},{"issue":"4","key":"2026090301450828100_cit117","doi-asserted-by":"publisher","first-page":"538","DOI":"10.2967\/jnumed.116.177659","article-title":"Practical\nImmuno-PET Radiotracer Design Considerations for Human Immune Checkpoint\nImaging","volume":"58","author":"Mayer","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"2","key":"2026090301450828100_cit118","doi-asserted-by":"publisher","first-page":"6","DOI":"10.7759\/cureus.7107","article-title":"Review of Lutetium-177-labeled Anti-prostate-specific\nMembrane Antigen Monoclonal Antibody J591 for the Treatment of Metastatic\nCastration-resistant Prostate Cancer","volume":"12","author":"Niaz","year":"2020","journal-title":"Cureus"},{"key":"2026090301450828100_cit119","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1475-2867-14-26","article-title":"Prostate specific membrane\nantigen (PSMA) expression in primary gliomas and breast cancer brain\nmetastases","volume":"14","author":"Nomura","year":"2014","journal-title":"Cancer Cell Int."},{"key":"2026090301450828100_cit120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nucmedbio.2017.05.005","article-title":"Tc-99m-labeled PSMA inhibitor: Biokinetics\nand radiation dosimetry in healthy subjects and imaging of prostate\ncancer tumors in patients","volume":"52","author":"Santos-Cuevas","year":"2017","journal-title":"Nucl. Med. Biol."},{"key":"2026090301450828100_cit121","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13014-017-0902-0","article-title":"Detection\nlevel and pattern of positive lesions using PSMA PET\/CT for staging\nprior to radiation therapy","volume":"12","author":"Schmidt-Hegemann","year":"2017","journal-title":"Radiat. Oncol."},{"issue":"4","key":"2026090301450828100_cit122","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00259-016-3563-6","article-title":"Ga-68-PSMA-HBED-CC PET imaging in breast carcinoma\npatients","volume":"44","author":"Sathekge","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"2026090301450828100_cit123","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2967\/jnumed.115.168393","article-title":"Pilot Comparison\nof Ga-68-RM2 PET\nand Ga-68-PSMA-11 PET in Patients with Biochemically Recurrent Prostate\nCancer","volume":"57","author":"Minamimoto","year":"2016","journal-title":"J. Nucl. Med."},{"issue":"6","key":"2026090301450828100_cit124","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s11307-017-1102-x","article-title":"Targeting\nProstate-Specific\nMembrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence\nof Prosthetic Groups on Tumor Uptake and Clearance Profile","volume":"19","author":"Bouvet","year":"2017","journal-title":"Molecular Imaging and Biology"},{"issue":"7","key":"2026090301450828100_cit125","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","article-title":"Lu-177-Labeled\nProstate-Specific Membrane Antigen Radioligand Therapy of Metastatic\nCastration-Resistant Prostate Cancer: Safety and Efficacy","volume":"57","author":"Baum","year":"2016","journal-title":"J. Nucl. Med."},{"key":"2026090301450828100_cit126","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.apradiso.2019.01.020","article-title":"Assessment\nof the radiation absorbed dose produced by Lu-177-iPSMA, Ac-225-iPSMA\nand (RaCl2)-Ra-223 to prostate cancer cell nuclei in a bone microenvironment\nmodel","volume":"146","author":"Azorin-Vega","year":"2019","journal-title":"Appl. Radiat. Isot."},{"issue":"6","key":"2026090301450828100_cit127","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2967\/jnumed.106.036699","article-title":"Identification and evaluation of\na new tumor cell-binding peptide, FROP-1","volume":"48","author":"Zitzmann","year":"2007","journal-title":"J.\nNucl. Med."},{"key":"2026090301450828100_cit128","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12929-018-0420-x","article-title":"Tc-99m-HYNIC-(tricine\/EDDA)-FROP\npeptide for MCF-7 breast tumor targeting and imaging","volume":"25","author":"Ahmadpour","year":"2018","journal-title":"J. Biomed. Sci."}],"container-title":["Bioconjugate Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.bioconjchem.0c00617","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/32\/1\/25\/67145630\/acs.bioconjchem.0c00617.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/32\/1\/25\/67145630\/acs.bioconjchem.0c00617.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:45:18Z","timestamp":1788414318000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/bcches\/article\/32\/1\/25\/368291\/Radiolabeled-Peptides-and-Antibodies-in-Medicine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":128,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12,16]]},"published-print":{"date-parts":[[2021,1,20]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.bioconjchem.0c00617","relation":{},"ISSN":["1043-1802","1520-4812"],"issn-type":[{"value":"1043-1802","type":"print"},{"value":"1520-4812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,16]]}}}